Special Issue "Mitochondrial Drugs for Neurodegenerative Diseases"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 August 2012)
Dr. P. Hemachandra Reddy
Neurogenetics Laboratory, Neuroscience Division, Oregon National Primate Research Center, West Campus, Oregon Health and Science University, 505 N.W., 185th Avenue Beaverton, OR 97006, USA
Phone: +1 503 418 2625 (office); +1 503 418 2627 (lab)
Fax: +1 503 418 2501
Interests: aging; neurodegenerative diseases; gene expression analysis; transgenic mouse models; mitochondrial biology; mitochondrial function/dysfunction; mitochondrial therapeutics; mitochondrial dynamics
Mitochondria, cytoplasmic organelles found in virtually every eukaryotic cell, are essential for life and death. In the last two decades tremendous progress has been made in mitochondrial research and has provided significant findings to link mitochondrial dysfunction in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Huntington’s disease. Further, recently, several groups developed mitochondrial-targeted antioxidants and tested in cell and mouse models of neurodegenerative diseases. The purpose of this special issue is to assess the current status of mitochondrial therapeutics, particularly mitochondrially targeted molecules in aging and age-related neurodegenerative diseases, and also to discuss the issues related to the development of molecules that cross blood brain barrier, reach mitochondria and protect mitochondria from the toxicity of mutant proteins and other toxic insults.
Prof. Dr. P. Hemachandra Reddy
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- Neurodegenerative Disease
- Mitochondrial-targeted antioxidants
- Cyclophilin D
- Mitochondrial permeability pore
- Alzheimer\'s Disease
- Parkinson\'s Disease
- Calcium Dyshomeostasis
Pharmaceuticals 2009, 2(3), 134-149; doi:10.3390/ph203134
Received: 29 September 2009; in revised form: 26 November 2009 / Accepted: 30 November 2009 / Published: 1 December 2009| Download PDF Full-text (213 KB) | Download XML Full-text
Pharmaceuticals 2009, 2(3), 150-167; doi:10.3390/ph2030150
Received: 19 November 2009; in revised form: 27 November 2009 / Accepted: 2 December 2009 / Published: 3 December 2009| Download PDF Full-text (328 KB) | Download XML Full-text
Review: Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets
Pharmaceuticals 2009, 2(3), 250-286; doi:10.3390/ph2030250
Received: 5 November 2009; in revised form: 21 December 2009 / Accepted: 22 December 2009 / Published: 23 December 2009| Download PDF Full-text (437 KB) | Download XML Full-text
Pharmaceuticals 2009, 2(3), 287-298; doi:10.3390/ph2030287
Received: 23 October 2009; in revised form: 14 December 2009 / Accepted: 16 December 2009 / Published: 23 December 2009| Download PDF Full-text (919 KB) | Download XML Full-text
Review: Oxidative Stress Induced Mitochondrial Failure and Vascular Hypoperfusion as a Key Initiator for the Development of Alzheimer Disease
Pharmaceuticals 2010, 3(1), 158-187; doi:10.3390/ph3010158
Received: 28 November 2009; in revised form: 11 January 2010 / Accepted: 14 January 2010 / Published: 19 January 2010| Download PDF Full-text (815 KB) | Download XML Full-text
Pharmaceuticals 2010, 3(2), 345-368; doi:10.3390/ph3020345
Received: 23 December 2009; in revised form: 20 January 2010 / Accepted: 25 January 2010 / Published: 28 January 2010| Download PDF Full-text (413 KB)
Pharmaceuticals 2010, 3(4), 839-915; doi:10.3390/ph3040839
Received: 31 December 2009; in revised form: 22 March 2010 / Accepted: 23 March 2010 / Published: 25 March 2010| Download PDF Full-text (810 KB)
Review: Unlocking the Door to Neuronal Woes in Alzheimer’s Disease: Aβ and Mitochondrial Permeability Transition Pore
Pharmaceuticals 2010, 3(6), 1936-1948; doi:10.3390/ph3061936
Received: 10 May 2010; in revised form: 10 June 2010 / Accepted: 14 June 2010 / Published: 14 June 2010| Download PDF Full-text (250 KB)
Review: Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer’s Disease
Pharmaceuticals 2012, 5(10), 1103-1119; doi:10.3390/ph5101103
Received: 5 September 2012; in revised form: 4 October 2012 / Accepted: 8 October 2012 / Published: 16 October 2012| Download PDF Full-text (460 KB) | Download XML Full-text
Pharmaceuticals 2013, 6(1), 108-123; doi:10.3390/ph6010108
Received: 5 November 2012; in revised form: 13 December 2012 / Accepted: 14 January 2013 / Published: 18 January 2013| Download PDF Full-text (241 KB) | Download XML Full-text
Last update: 18 May 2012